Funding

Indian Council of Medical Research

April 2020 to September 2020

₹ 25,000,000  (~US$ 350,000)

Project Brief

The PLACID trial was launched at the height of the COVID-19 pandemic to explore whether convalescent plasma collected from recovered patients could help improve outcomes for those battling moderate-to-severe COVID-19. As one of the earliest and largest multicenter studies on plasma therapy, it brought together clinicians, researchers, and policymakers to generate rapid, high-quality evidence at a time of intense global uncertainty. The findings played an important role in shaping national treatment guidelines and helped clarify the limits and potential of convalescent plasma as a therapeutic option for COVID-19.

Role & Responsbilities

In my capacity as a Co-Investigator, my responsibilities included the development of the trial protocol, the design of the trial, and planning the analysis of the ensuing data. Following the commencement of the study, my role transitioned to providing support to the data management and analysis teams. This study contributed to the ongoing efforts to identify effective treatments for COVID-19 and had major implications for the broader understanding of convalescent plasma therapy in the management of moderarte-to-severe COVID-19 disease and associated complications.